ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amlodipine

Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.

Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 2005170 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only570 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Boehringer Ingelheimits history only220 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Viatris130 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
Hanmi Pharmaceuticalits history only110 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Dr. Reddy's Laboratoriesits history only80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
HK inno.Nits history only50 open or runningphase 3since Feb 16, 2015Feb 10, 2014none ahead
Handokits history only40 open or runningphase 3since Jul 24, 2022Jul 21, 2020none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 9, 2009Feb 9, 2009none ahead
Yuhanits history only41 open or runningphase 4since Sep 4, 2023May 29, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Jan 8, 2016Feb 14, 2014none ahead

Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2005First study: phase 4 study in Myocardial IschemiaFirst studyNCT00143195 · 200 enrolled · Greece
  2. Sep 6, 20054 phase 4 studiesNCT00150384, NCT00159718, NCT00159692 and 1 more
  3. Feb 28, 2006Phase 3 study in HypertensionNCT00330785 · 1,250 enrolled · Canada, United Kingdom
  4. Dec 1, 20062 phase 4 studiesNCT00407537, NCT00412113
  5. Dec 21, 2006Phase 3 study in HypertensionNCT00415623 · 305 enrolled · Japan
  6. Sep 13, 2007Phase 3 study in HypertensionNCT00530946 · 165 enrolled · Japan
  7. Mar 30, 20082 phase 1 studiesNCT00649519, NCT00649402
  8. Oct 29, 2009Phase 1 study in HealthyNCT01004614 · 48 enrolled · Japan

TargetBeta

“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418
NifedipineruleBayerphase 418

Studies

All 13 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01004614Healthy · Japan1CompletedDec 200948
NCT00649519Healthy · United States1CompletedMay 200454
NCT00649402Healhty · United States1CompletedJun 200464
NCT00530946Hypertension · Japan3CompletedApr 2008165
NCT00415623Hypertension · Japan3CompletedOct 2007305
NCT00412113Dyslipidemias · United States4CompletedApr 2008245
NCT00407537Hypertension · Costa Rica, Croatia, Czechia and more4CompletedOct 20091,531
NCT00330785Hypertension · Canada, United Kingdom3Completed1,250
NCT00174330Hypertension · China4Completed330
NCT00159718Angina Pectoris · Croatia, Czechia, Estonia and more4Completed360
NCT00159692Hypertension4Completed739
NCT00150384Hypertension · United States4Completed500
NCT00143195Myocardial Ischemia · Greece4Completed200

How it is read

Names in the registry

  • “Amlodipine”, 44 entries
  • “amlodipine”, 14 entries
  • “Amlodipine 5 mg”, 9 entries
  • “Amlodipine 10 mg”, 6 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.